Delaware
|
68-0454536
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
Large accelerated filer o
|
Accelerated filer o
|
Non-accelerated filer o
(Do not check if a smaller reporting company)
|
Smaller reporting company x
|
Title of Securities to be Registered
|
Amount to be
registered(1)
|
Proposed maximum
offering price per
share(2)
|
Proposed maximum
aggregate offering
price
|
Amount of
registration fee
|
Common Stock, $0.01 par value per share
|
1,478,924
|
$1.165
|
$1,722,946
|
$235.01
|
(1) This represents an increase in the number of shares of common stock of the registrant reserved for issuance under the NovaBay Pharmaceuticals, Inc. 2007 Omnibus Incentive Plan pursuant to an evergreen provision contained therein. In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued resulting from stock splits, stock dividends, recapitalization or other similar transactions.
(2) Represents the average of the high and low prices of the Common Stock on January 10, 2013, as reported by NYSE MKT LLC, and is set forth solely for the purpose of calculating the filing fee pursuant to Rules 457(c) and 457(h) under the Act.
|
|
1.
|
The Company’s Annual Report on Form 10-K for the year ended December 31, 2011, as filed on March 27, 2012.
|
|
2.
|
The Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, as filed on November 1, 2012; the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2012, as filed on August 9, 2012; and the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2012, as filed on May 3, 2012.
|
|
3.
|
The Company’s Current Reports on Form 8-K filed on January 12, 2012, February 23, 2012, June 18, 2012, September 17, 2012, October 16, 2012, November 5, 2012, November 21, 2012, and December 6, 2012.
|
|
4.
|
The description of the Company’s Common Stock which is contained in the Company’s Current Report on Form 8-K filed on June 29, 2010.
|
Exhibit No.
|
Description of Document
|
|
3.1(1)
|
Amended and Restated Certificate of Incorporation
|
|
3.2(1)
|
Amended and Restated Bylaws
|
|
4.1
|
Reference is made to Exhibits 3.1 and 3.2 above.
|
|
5.1
|
Opinion of Cooley llp
|
Exhibit No. | Description of Document | |
23.1
|
Consent of OUM & Co. LLP
|
|
23.2
|
Consent of Davidson & Company LLP
|
|
23.3
|
Consent of Cooley llp (included in Exhibit 5.1)
|
|
24.1
|
Power of Attorney (included in Part II of this Registration Statement)
|
|
99.1(2)
|
NovaBay Pharmaceuticals, Inc. 2007 Omnibus Incentive Plan, as amended
|
|
99.2(3)
|
Forms of agreements for use under the NovaBay Pharmaceuticals, Inc. 2007 Omnibus Incentive Plan, as amended
|
|
|
(1)
|
Incorporated by reference to the exhibits of the same numbers from the Company’s report on Form 8-K (File No. 001-33678) as filed with the Commission on June 29, 2010.
|
|
(2)
|
Incorporated by reference to the the Plan as attached to the Company’s definitive proxy statement on Schedule 14A (File No. 001-33678) as filed with the Commission on April 26, 2012.
|
|
(3)
|
Incorporated by reference to Exhibit 10.3 to the Company’s Registration Statement on Form S-1 (File No. 333-140714) as filed with the Commission on May 29, 2007, as amended.
|
NovaBay Pharmaceuticals, Inc. | |
/s/ Ramin (“Ron”) Najafi, Ph.D. | |
Ramin (“Ron”) Najafi, Ph.D. | |
Chairman of the Board, President and Chief Executive Officer |
Signature
|
Title
|
Date
|
||
/s/ Ramin (“Ron”) Najafi, Ph.D. |
Chairman of the Board, Chief Executive Officer and President (principal executive officer)
|
January 10, 2013
|
||
Ramin (“Ron”) Najafi, Ph.D.
|
||||
/s/ Thomas J. Paulson |
Chief Financial Officer and Treasurer
(principal financial and accounting officer)
|
January 10, 2013
|
||
Thomas J. Paulson
|
||||
/s/ Charles J. Cashion |
Director
|
January 10, 2013
|
||
Charles J. Cashion
|
||||
/s/ Anthony Dailley, D.D.S. |
Director
|
January 10, 2013
|
||
Anthony Dailley, D.D.S.
|
Signature | Title |
Date
|
||
/s/ Paul E. Freiman |
Director
|
January 10, 2013
|
||
Paul E. Freiman
|
||||
/s/ Gail J. Maderis |
Director
|
January 10, 2013
|
||
Gail J. Maderis
|
||||
/s/ T. Alex McPherson, M.D., Ph.D. |
Director
|
January 10, 2013
|
||
T. Alex McPherson, M.D., Ph.D.
|
||||
/s/ Robert R. Tufts |
Director
|
January 10, 2013
|
||
Robert R. Tufts
|
||||
/s/ Tony D.S. Wicks |
Director
|
January 10, 2013
|
||
Tony D.S. Wicks
|
Exhibit No.
|
Description of Document
|
|
3.1(1)
|
Amended and Restated Certificate of Incorporation
|
|
3.2(1)
|
Amended and Restated Bylaws
|
|
4.1
|
Reference is made to Exhibits 3.1 and 3.2 above.
|
|
5.1
|
Opinion of Cooley llp
|
|
23.1
|
Consent of OUM and Co. LLP
|
|
23.2
|
Consent of Davidson & Company LLP
|
|
23.3
|
Consent of Cooley llp (included in Exhibit 5.1)
|
|
24.1
|
Power of Attorney (included in Part II of this Registration Statement)
|
|
99.1(2)
|
NovaBay Pharmaceuticals, Inc. 2007 Omnibus Incentive Plan, as amended
|
|
99.2(3)
|
Forms of agreements for use under the NovaBay Pharmaceuticals, Inc. 2007 Omnibus Incentive Plan, as amended
|
|
|
(1)
|
Incorporated by reference to the exhibits of the same numbers from the Company’s report on Form 8-K (SEC File No. 001-33678) as filed with the Commission on June 29, 2010.
|
|
(2)
|
Incorporated by reference to the Plan as attached to the Company’s definitive proxy statement on Schedule 14A (File No. 001-33678) as filed with the Commission on April 26, 2008.
|
|
(3)
|
Incorporated by reference to Exhibit 10.3 to the Company’s Registration Statement on Form S-1 (File No. 333-140714) as filed with the Commission on May 29, 2007, as amended.
|